학술논문

Refining Angiographic Biomarkers of Revascularization
Document Type
article
Source
Stroke. 44(9)
Subject
Brain Disorders
Neurosciences
Stroke
4.2 Evaluation of markers and technologies
Detection
screening and diagnosis
Good Health and Well Being
Aged
Aged
80 and over
Biomarkers
Cerebral Angiography
Cerebrovascular Circulation
Female
Fibrinolytic Agents
Humans
Infarction
Middle Cerebral Artery
Injections
Intra-Arterial
Male
Middle Aged
Predictive Value of Tests
Prognosis
Retrospective Studies
Thrombolytic Therapy
Trauma Severity Indices
Treatment Outcome
acute ischemic stroke
endovascular
intra-arterial therapy
modified TICI
revascularization
TIMI
Cerebral Angiographic Revascularization Grading Collaborators
Cardiorespiratory Medicine and Haematology
Clinical Sciences
Neurology & Neurosurgery
Language
Abstract
Background and purposeAngiographic revascularization grading after intra-arterial stroke therapy is limited by poor standardization, making it unclear which scale is optimal for predicting outcome. Using recently standardized criteria, we sought to compare the prognostic performance of 2 commonly used reperfusion scales.MethodsInclusion criteria for this multicenter retrospective study were acute ischemic stroke attributable to middle cerebral artery M1 occlusion, intra-arterial therapy, and 90-day modified Rankin scale score. Post-intra-arterial therapy reperfusion was graded using the Thrombolysis in Myocardial Infarction (TIMI) and Modified Thrombolysis in Cerebral Infarction (mTICI) scales. The scales were compared for prediction of clinical outcome using receiver-operating characteristic analysis.ResultsOf 308 patients, mean age was 65 years, and median National Institutes of Health Stroke Scale score was 17. The mean time from stroke onset to groin puncture was 305 minutes. There was no difference in the time to treatment between patients grouped by final TIMI (ie, 0 versus 1 versus 2 versus 3) or mTICI grades (ie, 0 versus 1 versus 2a versus 2b versus 3). Good outcome (modified Rankin scale, 0-2) was achieved in 32.5% of patients, and mortality rate was 25.3% at 90 days. There was a 6.3% rate of parenchymal hematoma type 2. In receiver-operating characteristic analysis, mTICI was superior to TIMI for predicting 90-day modified Rankin scale 0 to 2 (c-statistic: 0.74 versus 0.68; P